IL2RA and myeloid sarcoma: Due to the observation of positive healing effects on MS patients by starting the therapy with daclizumab; a monoclonal antibody that blocks IL-2 receptor alpha chain (IL-2Rα; CD25), NK cells gained importance for MS studies due to having IL-2R (172, 173).